Alnylam Pursues Value Framework To Accelerate Givlaari Access In EU
Following Approval Of The RNAi Therapeutic By The European Commission
Alnylam’s short-interfering RNA, Givlaari, has become the first treatment to be approved for preventing attacks of acute hepatic porphyria in the EU, and Alnylam wants to pursue a value-based agreement framework to accelerate patient and provider access.
